GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Shiller PE Ratio

BeiGene (HKSE:06160) Shiller PE Ratio : (As of May. 03, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BeiGene Shiller PE Ratio Historical Data

The historical data trend for BeiGene's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Shiller PE Ratio Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BeiGene Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BeiGene's Shiller PE Ratio

For the Biotechnology subindustry, BeiGene's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BeiGene's Shiller PE Ratio falls into.



BeiGene Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BeiGene's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, BeiGene's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.109/129.4194*129.4194
=-2.109

Current CPI (Dec. 2023) = 129.4194.

BeiGene Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201409 -0.108 100.428 -0.139
201412 -0.042 99.070 -0.055
201503 -0.113 99.621 -0.147
201506 -0.063 100.684 -0.081
201509 -0.155 100.392 -0.200
201512 -0.515 99.792 -0.668
201603 -0.543 100.470 -0.699
201606 -0.466 101.688 -0.593
201609 -0.621 101.861 -0.789
201612 -0.566 101.863 -0.719
201703 -0.777 102.862 -0.978
201706 -0.936 103.349 -1.172
201709 1.563 104.136 1.942
201712 -1.311 104.011 -1.631
201803 -1.255 105.290 -1.543
201806 -1.726 106.317 -2.101
201809 -1.489 106.507 -1.809
201812 -2.737 105.998 -3.342
201903 -1.727 107.251 -2.084
201906 -0.861 108.070 -1.031
201909 -3.056 108.329 -3.651
201912 -3.824 108.420 -4.565
202003 -2.809 108.902 -3.338
202006 -2.558 108.767 -3.044
202009 -2.868 109.815 -3.380
202012 -3.101 109.897 -3.652
202103 0.388 111.754 0.449
202106 -3.122 114.631 -3.525
202109 -2.827 115.734 -3.161
202112 -3.666 117.630 -4.033
202203 -2.582 121.301 -2.755
202206 -3.296 125.017 -3.412
202209 -3.218 125.227 -3.326
202212 -2.569 125.222 -2.655
202303 -2.041 127.348 -2.074
202306 -2.193 128.729 -2.205
202309 1.174 129.860 1.170
202312 -2.109 129.419 -2.109

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BeiGene  (HKSE:06160) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BeiGene Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BeiGene's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene (HKSE:06160) Business Description

Traded in Other Exchanges
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (HKSE:06160) Headlines

No Headlines